TY  - CONF

T1  - tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).

JO  - Journal of Clinical Oncology

PY  - 2014/05/20

AU  - Yardley DA

AU  - Brufsky A

AU  - Coleman RE

AU  - Conte PF

AU  - Cortes J

AU  - Glück S

AU  - Nabholtz J-MA

AU  - O'Shaughnessy J

AU  - Li L

AU  - Barton D

AU  - Beck RM et al

ED  - 

DO  - DOI: 10.1200/jco.2014.32.15_suppl.tps1146

PB  - American Society of Clinical Oncology (ASCO)

VL  - 32

IS  - 15_suppl

SP  - TPS1146

EP  - TPS1146

Y2  - 2025/10/10

ER  -